Table 3.

Risk of adverse outcomes with creatinine clearance (CrCl) among an age-stratified sample of 664 Rochester, Minnesota residents across methods used to measure or estimate creatinine generation

	Urinary CrCl	eCrClMuscle	eCrClAge,Sex	eCrClAge,Muscle
	Hazard ratios (95% confidence interval)
Adverse outcome	per 30 ml/min per 1.73m2 decline
Mortality	2.7 (2.3, 3.2)	2.9 (2.3, 3.5)	3.6 (2.9, 4.4)	3.5 (2.9, 4.2)
Cardiovascular disease	1.7 (1.4, 1.9)	1.8 (1.3, 2.4)	2.1 (1.7, 2.5)	2.1 (1.7, 2.5)
Coronary artery disease	1.4 (1.2, 1.7)	1.5 (1.1, 1.9)	1.8 (1.4, 2.3)	1.8 (1.4, 2.2)
Heart failure	2.3 (1.9, 2.9)	2.2 (1.6, 3.0)	3.1 (2.3, 4.0)	2.8 (2.2, 3.7)
Stroke	1.9 (1.5, 2.4)	2.1 (1.5, 2.8)	2.1 (1.6, 2.8)	2.2 (1.7, 3.0)
Peripheral vascular disease	1.7 (1.4, 2.1)	1.8 (1.3, 2.3)	2.0 (1.5, 2.5)	2.0 (1.6, 2.6)
	60-89 vs ≥90 ml/min per 1.73m2
Mortality	4.2 (3.0, 5.9)	3.3 (2.4, 4.6)	4.8 (3.4, 6.6)	4.0 (2.9, 5.6)
Cardiovascular disease	1.9 (1.3, 2.7)	2.0 (1.4, 2.8)	3.1 (2.2, 4.3)	3.1 (2.2, 4.3)
Coronary artery disease	1.5 (0.9, 2.3)	1.3 (0.8, 2.0)	1.9 (1.2, 2.9)	1.9 (1.3, 2.9)
Heart failure	3.4 (2.1, 5.5)	1.9 (1.2, 3.1)	4.2 (2.6, 6.7)	3.7 (2.3, 6.0)
Stroke	2.4 (1.4, 3.9)	2.6 (1.6, 4.1)	2.9 (1.8, 4.6)	2.9 (1.8, 4.7)
Peripheral vascular disease	2.0 (1.3, 3.2)	2.0 (1.3, 3.1)	3.0 (1.9, 4.6)	3.5 (2.3, 5.4)
	<60 vs ≥90 ml/min per 1.73m2
Mortality	8.8 (5.9, 13)	11 (6.4, 18)	16 (9.8, 25)	18 (11, 27)
Cardiovascular disease	3.1 (1.8, 5.0)	7.0 (3.3, 13)	8.1 (4.2, 14)	7.5 (3.8, 14)
Coronary artery disease	1.9 (0.9, 3.5)	4.2 (1.6, 8.8)	4.8 (2.2, 9.2)	4.8 (2.1, 9.4)
Heart failure	6.3 (3.4, 11)	11 (5.6, 21)	13 (6.8, 25)	15 (7.6, 27)
Stroke	3.9 (1.9, 7.4)	5.0 (1.5, 12)	7.9 (3.3, 16)	7.9 (3.4, 16)
Peripheral vascular disease	3.6 (1.9, 6.5)	4.7 (1.8, 10)	6.7 (3.0, 13)	9.3 (4.4, 18)

eCrCl, estimated creatinine clearance.